IBA Lifesciences

Executive Summary

IBA Lifesciences, founded in 1988 and headquartered in Göttingen, Germany, is a privately held biotechnology company specializing in affinity purification tools for protein and cell isolation. Its proprietary Strep-tag® technology is widely adopted in academic and industrial life sciences research, providing high-performance solutions for proteomics, diagnostics, and antibody development. The company serves a global customer base and maintains a strong reputation for reliability and innovation in the research tools market. While it operates in a competitive landscape with established players, IBA's niche expertise and long-standing presence position it as a stable but mature business. Growth prospects are modest, as the company has likely reached a steady state in its core market, with potential expansion into adjacent areas such as diagnostics or therapeutics requiring strategic investments or partnerships.

Upcoming Catalysts (preview)

• Q3 2026Launch of enhanced Strep-tag® product line for advanced proteomics60% success
• TBDStrategic partnership with a pharmaceutical company for drug target purification30% success
• Q1 2027Entry into clinical diagnostics with a novel capture reagent20% success